15-Deoxyspergualin (15-DOS) has a curative effect on the development of SLE-like autoimmune disease in MRL/1 mice.
Treating MRL/1pr mice, which spontaneously develop systemic lupus erythematosus and rheumatoid arthritis, with 15-DOS resulted in a decrease in the amount of autoantibodies and inhibited proteinuria of the developing glomerulonephritis with an improved survival rate of these autoimmune mice. 15-DOS treatment also lowered the percentage of animals with swollen lymph nodes and inhibited the development of splenomegaly. In the established disease 15-DOS returned urine-protein values and renal function (serum urea and creatinine) to normal levels. Circulating rheumatoid factor and autoantibodies to double-stranded DNA were reduced and the increase in paw volume (signs of a polyarthritis) was inhibited.
Schorlemmer
H U
HU
Research Laboratories of Behringwerke AG, Marburg/Lahn, FRG.
Bartlett
R R
RR
Seiler
F R
FR
D000818:Animals; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D001323:Autoantibodies / Q000032:analysis; D001327:Autoimmune Diseases / Q000188:drug therapy*; D005260:Female; D005921:Glomerulonephritis / Q000188:drug therapy / Q000517:prevention & control; D006146:Guanidines / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007274:Injections, Intraperitoneal; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy*; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D012217:Rheumatoid Factor / Q000032:analysis
D001323:Autoantibodies; D006146:Guanidines; D007166:Immunosuppressive Agents; D012217:Rheumatoid Factor; C037258:gusperimus